Key Highlights

  • The FDA approved Moderna's supplemental Biologics License Application for updated Spikevax and mNEXSPIKE formulas.
  • The updated vaccines target the LP.8.1 variant strain.
  • Approval covers the 2026-2027 vaccination season.
  • The approval was announced August 27, 2026.

Updated COVID-19 Vaccines Cleared for the New Season

Moderna Inc. (NASDAQ:MRNA) announced on August 27, 2026 that the FDA has approved its supplemental Biologics License Application (sBLA) covering updated formulas of Spikevax and mNEXSPIKE for the 2026-2027 season. The updated formulations are designed around the LP.8.1 variant strain, reflecting the periodic strain-composition updates that COVID-19 vaccines have required as the virus continues to evolve.

Spikevax and mNEXSPIKE represent Moderna's (NASDAQ:MRNA) core respiratory Vaccine franchise, and annual approval of updated formulas is a recurring regulatory event for the company, similar in structure to the seasonal update process used for influenza vaccines.

What This Means for the Season Ahead

With FDA approval secured, Moderna (NASDAQ:MRNA) can proceed with distribution of the updated formulas ahead of the upcoming respiratory illness season. The approval itself is a regulatory and supply-chain milestone rather than a new efficacy claim, since it reflects an update to the vaccine's antigenic composition rather than a change to the underlying platform.

Market Reaction

Despite the approval, Moderna (NASDAQ:MRNA) shares fell 4.6% to $142.77, with a market Capitalization of approximately $57 billion. The decline suggests the approval itself was largely anticipated by the market, with broader considerations — such as overall vaccination Demand trends and Revenue expectations for the season — likely weighing more heavily on the stock than the regulatory clearance.

What did the FDA approve for Moderna on August 27, 2026?

The FDA approved Moderna's (NASDAQ:MRNA) supplemental Biologics License Application for updated Spikevax and mNEXSPIKE formulas targeting the LP.8.1 variant for the 2026-2027 season.

Why did Moderna shares fall despite the approval?

The approval was largely expected, and broader demand and revenue expectations for the vaccination season appear to have weighed more on the stock than the regulatory news itself.

What variant strain do the updated vaccines target?

The updated Spikevax and mNEXSPIKE formulas target the LP.8.1 variant strain.